Accuray Inc (ARAY)
1.745
-0.06
(-3.59%)
USD |
NASDAQ |
Nov 14, 16:00
1.85
+0.10
(+6.02%)
After-Hours: 20:00
Accuray Research and Development Expense (Quarterly): 9.529M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 12.12M |
| June 30, 2024 | 9.529M |
| March 31, 2024 | 10.91M |
| December 31, 2023 | 15.28M |
| September 30, 2023 | 14.01M |
| June 30, 2023 | 14.19M |
| March 31, 2023 | 14.21M |
| December 31, 2022 | 14.64M |
| September 30, 2022 | 14.09M |
| June 30, 2022 | 14.57M |
| March 31, 2022 | 14.10M |
| December 31, 2021 | 14.70M |
| September 30, 2021 | 14.38M |
| June 30, 2021 | 15.36M |
| March 31, 2021 | 13.27M |
| December 31, 2020 | 11.96M |
| September 30, 2020 | 12.15M |
| June 30, 2020 | 12.22M |
| March 31, 2020 | 11.16M |
| December 31, 2019 | 13.06M |
| September 30, 2019 | 13.34M |
| June 30, 2019 | 16.05M |
| March 31, 2019 | 12.91M |
| December 31, 2018 | 13.64M |
| September 30, 2018 | 13.89M |
| Date | Value |
|---|---|
| June 30, 2018 | 14.59M |
| March 31, 2018 | 13.91M |
| December 31, 2017 | 14.66M |
| September 30, 2017 | 14.09M |
| June 30, 2017 | 13.26M |
| March 31, 2017 | 12.48M |
| December 31, 2016 | 11.94M |
| September 30, 2016 | 12.23M |
| June 30, 2016 | 14.16M |
| March 31, 2016 | 13.27M |
| December 31, 2015 | 14.93M |
| September 30, 2015 | 14.30M |
| June 30, 2015 | 14.85M |
| March 31, 2015 | 12.84M |
| December 31, 2014 | 13.92M |
| September 30, 2014 | 14.15M |
| June 30, 2014 | 13.58M |
| March 31, 2014 | 13.76M |
| December 31, 2013 | 13.44M |
| September 30, 2013 | 12.95M |
| June 30, 2013 | 14.69M |
| March 31, 2013 | 15.70M |
| December 31, 2012 | 17.24M |
| September 30, 2012 | 18.57M |
| June 30, 2012 | 21.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.529M
Minimum
Jun 2024
15.36M
Maximum
Jun 2021
13.30M
Average
14.05M
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 407.00M |
| Baxter International Inc | 129.00M |
| AngioDynamics Inc | 6.285M |
| Masimo Corp | 48.30M |
| Perspective Therapeutics Inc | 9.275M |